Spironolactone; the ultimate blocker of RAAS cascade in hypertensive patients with special reference to its cardiovascular benefits: Revisiting the forgotten ways

Authors

  • Kumar Kota Sunil Department of Endocrinology, Medwin Hospital, Andhra Pradesh
  • Jammula Sruti Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Khodasingi, Ambapua, Berhampur-760010, Orissa
  • Krishna Kota Siva Department of Anaesthesia, Central Security Hospital, Riyadh
  • Panda Sandip Department of Cardiology, Jipmer Puducherry
  • Kumar Meher Lalit Department of Medicine, Mkcg Medical College, Berhampur- 760004, Orissa
  • D Modi Kirtikumar Head of the Department, Endocrinology, Medwin Hospital

DOI:

https://doi.org/10.3329/bjms.v11i2.8664

Keywords:

Hypertension, microvascular, macrovascular, spironolactone

Abstract

Hypertension is a major risk factor for various macro and microvascular complications in a patient with diabetes. Control of hypertension is of paramount importance in the care of a diabetes subject. The goals for blood pressure in diabetes subjects are below 130/ 80 mmHg and below 125/75 mmHg if accompanying renal impairment is there. Spironolactone is a medication that has been used to treat high blood pressure since the 1960s. While there is some belief spironolactone reduces blood pressure, there are concerns due to the potential for this drug to cause adverse effects. Previous Meta analysis has shown that spironolactone reduces systolic/diastolic blood pressure by approximately 20/7 mmHg compared to placebo. Spironolactone has also been shown to decrease morbidity and mortality in patients with heart failure. We have tried to emphasize upon the usage of this old but important drug in management of resistant hypertension with reference to its mode of action, benefits and recent studies pertinent to cardiovascular benefits of spironolactone.

Data Source:We searched PUBMED and MEDLINE database for relevant articles including key words. References of each article were further reviewed for final synthesis of the manuscript.

DOI: http://dx.doi.org/10.3329/bjms.v11i2.8664

Bangladesh Journal of Medical Science Vol. 11 No. 02 April 2012: 80-86

Downloads

Download data is not yet available.
Abstract
301
PDF
121

Downloads

Additional Files

Published

2012-07-24

How to Cite

Sunil, K. K., Sruti, J., Siva, K. K., Sandip, P., Lalit, K. M., & Kirtikumar, D. M. (2012). Spironolactone; the ultimate blocker of RAAS cascade in hypertensive patients with special reference to its cardiovascular benefits: Revisiting the forgotten ways. Bangladesh Journal of Medical Science, 11(2), 80–86. https://doi.org/10.3329/bjms.v11i2.8664

Issue

Vol. 11 No. 2 (2012)

Section

Review Article

License

Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:

  1. Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.

  2. Creative Commons Licence
    Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.